CEFADROXIL

SynDRA canonical compound SYN0016060 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	SLC22A8
Mechanism of action	Bacterial cell wall synthesis inhibitor
Indication	pharyngitis \| skin infections \| tonsillitis \| urinary tract infections \| urinary tract infections, skin infections, tonsillitis, pharyngitis
Disease area	infectious disease \| infectious disease \| infectious disease, otolaryngology \| otolaryngology \| otolaryngology

All known targets

SLC15A1
SLC15A2
SLC22A6
SLC22A8
dacA
dacB
dacC
ftsI
mrcA
mrcB
mrdA

Mechanisms of action (all sources)

Bacterial cell wall synthesis inhibitor
mrcA INHIBITOR
mrcB INHIBITOR
dacC INHIBITOR
mrdA INHIBITOR
ftsI INHIBITOR
dacA INHIBITOR
dacB INHIBITOR

Bioactivity evidence (ChEMBL activities table — not curator-asserted)

Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)

NF2L2

Drug classes

Anti-Bacterial Agents
Anti-Infective Agents

ATC classes

J01D · OTHER BETA-LACTAM ANTIBACTERIALS

Cross-references

PubChem CID: 47965
ChEMBL: CHEMBL1644
DrugBank: DB01140
ChEBI: CHEBI:53667
KEGG: D00257
RxNorm: 1545975
PDB: A1APP
Wikipedia: Cefadroxil
TTD: D0X9ZC
LINCS BRD: BRD-K63242551

Synonyms

Reported adverse events

Agranulocytosis
Hypersensitivity
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Dyspepsia

Look up CEFADROXIL in the interactive SynDRA portal →